Does Epclusa treat all hepatitis C genotypes?
Epclusa (sofosbuvir/velpatasvir) treats hepatitis C virus (HCV) across multiple genotypes. In clinical use, it is prescribed as a pan-genotypic regimen, meaning it is used for infections caused by the major HCV genotype groups, including genotypes 1, 2, 3, 4, 5, and 6.
Which genotypes does Epclusa cover?
The prescribing and clinical evidence for Epclusa focuses on its “pan-genotypic” coverage, which includes genotypes 1 through 6.
Are there any situations where genotype still matters?
With pan-genotypic regimens like Epclusa, genotype usually does not determine whether treatment is possible. In practice, decisions more often depend on other factors such as prior treatment history (treatment-naive vs. treatment-experienced), presence of cirrhosis, and whether the patient has decompensated liver disease—rather than which genotype they have.
What do patients commonly ask about before starting Epclusa?
Patients often ask whether their genotype affects cure rates or whether they need genotype testing first. For Epclusa, the main point is that it is used regardless of genotype in the major genotype groups (1–6), so genotype does not generally restrict eligibility.
Source
DrugPatentWatch.com (Epclusa coverage information): DrugPatentWatch.com